COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency

NCT04724642 · clinicaltrials.gov ↗

UNKNOWN

Status

110

Enrollment

OTHER_GOV

Sponsor class

Conditions

Allogenic Hematopoietic Cell Transplant
CAR-T Therapy
Primary Immunodeficiency

Sponsor

Tel-Aviv Sourasky Medical Center